BEIGENE Secures Global Exclusive Rights to Develop Trispecific Therapy Through Huahui Anjian Partnership

Stock News04-27

BEIGENE (06160) announced that on April 24, 2026, its wholly-owned subsidiary, BEIGENE Guangzhou, entered into a collaboration agreement with Huahui Anjian. Under the agreement, Huahui Anjian granted BEIGENE Guangzhou an exclusive option to obtain a worldwide, exclusive license for the development, production, and commercialization of Huahui Anjian's investigational trispecific compound targeting PD-1, CTLA-4, and VEGF-A—including HH160—and any products containing such compounds, for all indications.

Pursuant to the agreement, BEIGENE Guangzhou will pay Huahui Anjian an upfront fee of $20 million. If BEIGENE Guangzhou exercises the option within a specified period, Huahui Anjian will be eligible to receive an additional option exercise payment of $100 million. Upon achieving development and regulatory milestones, Huahui Anjian may receive up to $374 million in payments. Following the attainment of sales milestones, Huahui Anjian could receive up to $1.53 billion. Additionally, Huahui Anjian is entitled to receive tiered royalties.

Furthermore, Huahui Anjian has agreed to compensate BEIGENE Guangzhou for the licensing of related intellectual property to Huahui Anjian—limited to the extent necessary for Huahui Anjian to fulfill its obligations under the agreement—once relevant milestones are achieved.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149251521?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149251521","market":"other","top_or_hot":-1,"title":"BEIGENE Secures Global Exclusive Rights to Develop Trispecific Therapy Through Huahui Anjian Partnership","media":"Stock News","content":"<p>BEIGENE (06160) announced that on April 24, 2026, its wholly-owned subsidiary, BEIGENE Guangzhou, entered into a collaboration agreement with Huahui Anjian. Under the agreement, Huahui Anjian granted BEIGENE Guangzhou an exclusive option to obtain a worldwide, exclusive license for the development, production, and commercialization of Huahui Anjian's investigational trispecific compound targeting PD-1, CTLA-4, and VEGF-A—including HH160—and any products containing such compounds, for all indications.</p>\n<p>Pursuant to the agreement, BEIGENE Guangzhou will pay Huahui Anjian an upfront fee of $20 million. If BEIGENE Guangzhou exercises the option within a specified period, Huahui Anjian will be eligible to receive an additional option exercise payment of $100 million. Upon achieving development and regulatory milestones, Huahui Anjian may receive up to $374 million in payments. Following the attainment of sales milestones, Huahui Anjian could receive up to $1.53 billion. Additionally, Huahui Anjian is entitled to receive tiered royalties.</p>\n<p>Furthermore, Huahui Anjian has agreed to compensate BEIGENE Guangzhou for the licensing of related intellectual property to Huahui Anjian—limited to the extent necessary for Huahui Anjian to fulfill its obligations under the agreement—once relevant milestones are achieved.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BEIGENE Secures Global Exclusive Rights to Develop Trispecific Therapy Through Huahui Anjian Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBEIGENE Secures Global Exclusive Rights to Develop Trispecific Therapy Through Huahui Anjian Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-27 19:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIGENE (06160) announced that on April 24, 2026, its wholly-owned subsidiary, BEIGENE Guangzhou, entered into a collaboration agreement with Huahui Anjian. Under the agreement, Huahui Anjian granted BEIGENE Guangzhou an exclusive option to obtain a worldwide, exclusive license for the development, production, and commercialization of Huahui Anjian's investigational trispecific compound targeting PD-1, CTLA-4, and VEGF-A—including HH160—and any products containing such compounds, for all indications.</p>\n<p>Pursuant to the agreement, BEIGENE Guangzhou will pay Huahui Anjian an upfront fee of $20 million. If BEIGENE Guangzhou exercises the option within a specified period, Huahui Anjian will be eligible to receive an additional option exercise payment of $100 million. Upon achieving development and regulatory milestones, Huahui Anjian may receive up to $374 million in payments. Following the attainment of sales milestones, Huahui Anjian could receive up to $1.53 billion. Additionally, Huahui Anjian is entitled to receive tiered royalties.</p>\n<p>Furthermore, Huahui Anjian has agreed to compensate BEIGENE Guangzhou for the licensing of related intellectual property to Huahui Anjian—limited to the extent necessary for Huahui Anjian to fulfill its obligations under the agreement—once relevant milestones are achieved.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0307460666.USD","symbol_name":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","start_time":0,"source_url":"","article_id":"1149251521","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149251521","pubTimestamp":1777288478,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BEIGENE (06160) announced that on April 24, 2026, its wholly-owned subsidiary, BEIGENE Guangzhou, entered into a collaboration agreement with Huahui Anjian. Under the agreement, Huahui Anjian granted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","688235":"百济神州","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK1500":"做空集合股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","06978":"永泰生物-B","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","BK1588":"回港中概股","BK1161":"生物科技","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","ONC":"百济神州","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","06160":"百济神州","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4139":"生物科技","BK1583":"高瓴概念","BK0239":"医药制造"},"translate_title":"百济神州通过华辉安建合作获得三特异性疗法全球独家开发权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"688235":1,"06978":1,"06160":1,"ONC":1},"content_text":"BEIGENE (06160) announced that on April 24, 2026, its wholly-owned subsidiary, BEIGENE Guangzhou, entered into a collaboration agreement with Huahui Anjian. Under the agreement, Huahui Anjian granted BEIGENE Guangzhou an exclusive option to obtain a worldwide, exclusive license for the development, production, and commercialization of Huahui Anjian's investigational trispecific compound targeting PD-1, CTLA-4, and VEGF-A—including HH160—and any products containing such compounds, for all indications.\nPursuant to the agreement, BEIGENE Guangzhou will pay Huahui Anjian an upfront fee of $20 million. If BEIGENE Guangzhou exercises the option within a specified period, Huahui Anjian will be eligible to receive an additional option exercise payment of $100 million. Upon achieving development and regulatory milestones, Huahui Anjian may receive up to $374 million in payments. Following the attainment of sales milestones, Huahui Anjian could receive up to $1.53 billion. Additionally, Huahui Anjian is entitled to receive tiered royalties.\nFurthermore, Huahui Anjian has agreed to compensate BEIGENE Guangzhou for the licensing of related intellectual property to Huahui Anjian—limited to the extent necessary for Huahui Anjian to fulfill its obligations under the agreement—once relevant milestones are achieved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149251521","isCrawlerRequest":true}